Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →
Help us improve your experience. Please confirm your investor type:
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
LABD ETF · Direxion Daily S&P Biotech Bear 3X Shares ETF
Performance & flows
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -30.35% | -22.21% | -84.39% | -90.57% | -92.81% | -15.28% | -15.28% | -34.21% | |
| Flows |
Key fund info
Essentials
Enterprise
Advertisement
Risk profile
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | -22.21% | -84.39% | -90.57% | -92.81% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Exposure
The LABD ETF provides synthetic exposure. It uses derivatives to replicate the index's performance, so we do not display its exposure breakdown.
To find out more about LABD's exposure, please refer to the as provided by Direxion.
Sustainability
Issuer
| AuM | ||
|---|---|---|
SOXL | Direxion Daily Semiconductor Bull 3X Shares ETF | €13B |
SPXL | Direxion Daily S&P 500 Bull 3X Shares | €4.89B |
TSLL | Direxion Daily TSLA Bull 2X Shares | €3.92B |
TECL | Direxion Daily Technology Bull 3X Shares ETF | €3.89B |
TMF | Direxion Daily 20+ Year Treasury Bull 3X Shares ETF - USD | €2.36B |
Frequently asked questions about LABD
What does Direxion Daily S&P Biotech Bear 3X Shares ETF, LABD, invest in?
LABD is a Passive ETF. This ETF provides inverse exposure (-3x) to Equally Weighted US Biotechnology Equities.
Which benchmark or index does LABD replicate?
LABD tracks the S&P Biotechnology Select Industry Index - USD, through a unfunded swap replication method.
What is the Total Expense ratio (TER) of LABD?
LABD carries a total expense ratio (TER) of 1.08%, indicating the annual cost for holding the fund.
When was LABD launched?
LABD was introduced to the market on May 28, 2015. It trades on United States
Who is the ETF issuer of LABD?
Direxion Daily S&P Biotech Bear 3X Shares ETF, LABD, is provided by Direxion. Learn more about Direxion here.
What is the current assets under management (AUM) of LABD?
LABD oversees €73M in assets as of April 23, 2026.
How has LABD performed lately?
Based on data from April 23, 2026, LABD returned -30.35% over the past month, -22.21% over the last three months and -34.21% year-to-date.
What are the latest inflows or outflows for LABD?
As of April 23, 2026, LABD recorded net flows of +€21M over the last month and +€41M year-to-date.
Does LABD distribute dividends?
LABD follows a distributing dividend policy, meaning it pays out income to investors. As of April 23, 2026, its 12-month trailing yield was 6.84%.
What is the base currency of LABD?
The base currency of LABD is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
Privacy policy | Cookie policy | | Terms of use | Imprint
